 VICTORIA, British Columbia--BUSINESS WIRE--- IPA Deltavariant--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA, a leader in full-service, therapeutic antibody discovery and development, today announced that it will be presenting at the H.C. Wainwright Annual Global Investment Conference being held virtually on September 13-15, 2021. Jennifer Bath, CEO of ImmunoPrecise, will provide an overview of the Companys business during the live presentation and will be available to 